DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.
Elrick H., Stimmler L., Hlad CJ, Arai Y.Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab1964;24:1076-82.
4.
Unger RH, Eisentraut AMEntero-insular axis. Arch Int Med1969;123:261-6.
5.
Marks V., Morgan L.The entero-insular axis in Recent advances in diabetes, Nattrass M, Santiago (eds) Churchill Livingstone, London1984;1:55-71.
6.
Nauck M., Stockmann F., Ebert R., Creuzfeldt W.Reduced incretin effecting type 2 (non-insulin-dependent) diabetes . Diabetologia1986;29:46-52.
7.
Nauck MA, Heimesaat MM, Orskov C. et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest1993;91:301-07.
8.
Estall JL, Drucker DJGlucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des2006;12:1731-50.
9.
Drucker DJThe biology of incretin hormones. Cell Metabolism2006;3:153-65.
10.
Drucker DJThe role of gut hormones in glucose homeostasis. J Clin Invest2007;117:24-32.
11.
Green BD, Flatt PR, Bailey CJDipeptidyl peptidase 4 (DPP 4) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc Dis Res2006;3:159-65.
12.
Bailey CJOral antidiabetic drugs. Encyclopedia of Molecular PharmacologyOffermans S, Rosenthal W (eds) Springer (in press).
13.
Sitagliptin, Summary of Product Characteristicshttp://emc.medicines.org.uk/
14.
Herman G., Bergman A., Wagner JASitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug-drug interactions (DDI). Diabetologia2006;49:(suppl 1) Abstract 0795.
15.
Hermann G., Hanefeld M., Wu M. et al. Effect of MK-0431, a dipeptidyl peptidase 4 (DPP-4) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes2005;54:Abstract 541-P.
16.
Nonaka K., Kakikawa T., Sato et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in Japanese patients with type 2 diabetes. Diabetologia2006;49(suppl1):Abstract 0038.
17.
Raz I., Hanefeld M., Xu L. et al. Efficacy and safety of sitagliptin over 18 weeks in patients with type 2 diabetes. Diabetologia2006;49:(suppl 1).Abstract 0794.
18.
Aschner P., Kipnes M., Lunceford J. et al. Effect of the dipeptidyl peptidase-4 sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care2006;29:2632-7.
19.
Goldstein BJ , Feinglos MN, Lunceford et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care (in press), published online May 7 2007.
20.
Rosenstock J., Brazg R., Andryuk P. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter , Clin Therapeutics2006;28:1556-68. randomized, double-blind, placebo-controlled, parallel-group study. Clin Therapeutics2006;28:1556-68.
21.
Nauck MA, Meininger G., Sheng D. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately confonylurea, glipizide, in patients with type 2 diabete de ately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab2007;9:194-205.
22.
Charbonnel B., Karisik A., Liu J. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care2006;29:2638-43.
23.
Brazg R., Xu L., Dalla Man C. et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and b-cell function in patients with type 2 diabetes. Diabetes Obes Metab2007;9:186-93.
24.
Nathan DM, Buse JB, Davidson ME et al. Management of hyperlgycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia2006;49:1711-21 and Diabetes Care2006;29:1963-72.
25.
Mistry G., Bergman A., Wen-Lin L. et al. Effects of sitagliptin on the pharmacokinetics (PK) of rosiglitazone in healthy subjects. Diabetes2006; Abstract 2001-PO.
26.
Ruddy MK, Bergman AJ, Zheng W. et al. Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea, glyburide. Diabetes2006 .Abstract 558-P.
27.
Vilsboll T. , Knop FKDPP 4 inhibitors current evidence and future directions. Br J Diabetes Vasc Dis2007;2:69-74.
